Role of intestinal microecological dysregulation in development of metabolic-associated fatty liver disease

doi:10.3877/cma.j.issn.1674-0785.2023.07.012

Abstract

Abstract:

Metabolic-associated fatty liver disease (MAFLD) is a serious public health threat and its pathogenesis is still not completely clear. Studies have shown that the intestinal microbiota and its metabolites have an important role in the development of MAFLD. In this review, we focus on the key mechanisms by which the intestinal microbiota and its metabolites influence MAFLD. In addition, we also discuss the treatment of MAFLD by modulating the intestinal microbiota through probiotics, prebiotics, synbiotics, and fecal microbiota transplantation.

Key words: Metabolic-related fatty liver disease, Intestinal microbiota, Lipopolysaccharide, Short-chain fatty acids, Choline

Daya Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Da Li, Feihu Bai. Role of intestinal microecological dysregulation in development of metabolic-associated fatty liver disease[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 828-833.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2023.07.012

https://zhlcyszz.cma-cmc.com.cn/EN/Y2023/V17/I07/828

References 85

1	Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease [J]. Gastroenterology, 2020, 158(7): 1999-2014. e1.
2	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement [J]. J Hepatol, 2020, 73(1): 202-209.
3	Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease [J]. J Hepatol, 2021, 75(2): 454-461.
4	Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study [J]. J Clin Endocrinol Metab, 2022, 107(2): e745-e755.
5	Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study [J]. Diabetes Metab Syndr Obes, 2022, 15: 2311-2322.
6	Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD [J]. Clin Gastroenterol Hepatol, 2023, 21(3): 619-629. e7.
7	Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups [J]. Liver Int, 2022, 42: 277-287.
8	Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease [J]. Clin Gastroenterol Hepatol, 2021, 19: 2161-2171.
9	Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study [J]. BMC Gastroenterol, 2021, 21: 212.
10	Huang YP, Zhang S, Zhang M, et al. Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study [J]. BMJ Open, 2021, 11: e056260.
11	Guan C, Fu S, Zhen D, et al. Metabolic (dysfunction)-associated fatty liver disease in Chinese patients with type 2 diabetes from a subcenter of the national metabolic management center [J]. J Diabetes Res, 2022, 2022: 8429847.
12	Fouad Y, Esmat G, Elwakil R, et al. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease [J]. Saudi J Gastroenterol, 2022, 28(1): 3-20.
13	Shao CX, Ye J, Dong Z, et al. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease [J]. Ther Adv Chronic Dis, 2021, 12: 20406223211033119.
14	Ye J, Zhuang X, Li X, et al. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation [J]. Metabolism, 2022, 136: 155294.
15	Yu Q, Wu L, Ji J, et al. Gut Microbiota, peroxisome proliferator-activated receptors, and hepatocellular carcinoma [J]. J Hepatocell Carcinoma, 2020, 7: 271-288.
16	Seo DO, Holtzman DM. Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer's disease [J]. J Gerontol A Biol Sci Med Sci, 2020, 75(7): 1232-1241.
17	Wu J, Wang K, Wang X, et al. The role of the gut microbiome and its metabolites in metabolic diseases [J]. Protein Cell, 2021, 12(5): 360-373.
18	Chen J, Vitetta L. Gut Microbiota metabolites in NAFLD pathogenesis and therapeutic implications [J]. Int J Mol Sci, 2020, 21(15): 5214.
19	Vallianou N, Christodoulatos GS, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives [J]. Biomolecules, 2021, 12(1): 56.
20	Yang L, Dai Y, He H, et al. Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients [J]. Front Microbiol, 2022, 13: 969757.
21	Riordan SM, Duncombe VM, Thomas MC, et al. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis [J]. Gut, 2002, 50(1): 136-138.
22	Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH [J]. Hepatology, 2013, 57(2): 601-609.
23	Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease [J]. Clin Gastroenterol Hepatol, 2013, 11(7): 868-875.e1-3.
24	Da Silva HE, Teterina A, Comelli EM, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance [J]. Sci Rep, 2018, 8(1): 1466.
25	Wang B, Jiang X, Cao M, et al. Altered Fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease [J]. Sci Rep, 2016, 6: 32002.
26	Schwimmer JB, Johnson JS, Angeles JE, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease [J]. Gastroenterology, 2019, 157(4): 1109-1122.
27	Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis [J]. Lipids Health Dis, 2021, 20(1): 22.
28	Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for mon-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease [J]. Cell Metab, 2019, 30(3): 607.
29	Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease [J]. FEMS Microbiol Ecol, 2015, 91(2): 1-9.
30	Li NN, Li W, Feng JX, et al. High alcohol-producing Klebsiella pneumoniae causes fatty liver disease through 2,3-butanediol fermentation pathway in vivo [J]. Gut Microbes, 2021, 13(1): 1979883.
31	Schroeder BO, Birchenough G, Ståhlman M, et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration [J]. Cell Host Microbe, 2018, 23(1): 27-40. e7.
32	Jia W, Rajani C. The influence of gut microbial metabolism on the development and progression of non-alcoholic fatty liver disease [J]. Adv Exp Med Biol, 2018, 1061: 95-110.
33	Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability [J]. Cell Mol Gastroenterol Hepatol, 2015, 1(2): 222-232.
34	Zhang Z, Zhang H, Chen T, et al. Regulatory role of short-chain fatty acids in inflammatory bowel disease [J]. Cell Commun Signal, 2022, 20(1): 64.
35	Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy [J]. J Hepatol, 2020, 72(3): 558-577.
36	Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome [J]. Nutrients, 2020, 12(4): 1107.
37	Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions [J]. Science, 2012, 336(6086): 1262-1267.
38	Liu W, Luo X, Tang J, et al. A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier [J]. Eur J Nutr, 2021, 60(5): 2317-2330.
39	Zhang S, Zhao J, Xie F, et al. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease [J]. Obes Rev, 2021, 22(11): e13316.
40	Deng M, Qu F, Chen L, et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD [J]. J Endocrinol, 2020, 245(3): 425-437.
41	Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH [J]. EMBO Mol Med, 2019, 11(2): e9302.
42	Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells [J]. Nat Immunol, 2016, 17(6): 618-625.
43	Godlewska U, Bulanda E, Wypych TP. Bile acids in immunity: bidirectional mediators between the host and the microbiota [J]. Front Immunol, 2022, 13: 949033.
44	Li T, Chiang J. Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease [J]. Hepatobiliary Surg Nutr, 2020, 9(2): 152-169.
45	Li Y, Chen H, Ke Z, et al. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice [J]. Biochem Biophys Res Commun, 2020, 521(3): 639-645.
46	Gillard J, Clerbaux LA, Nachit M, et al. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice [J]. JHEP Rep, 2022, 4(1): 100387.
47	Rivera-Andrade A, Petrick JL, Alvarez CS, et al. Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala [J]. Aliment Pharmacol Ther, 2022, 56(2): 321-329.
48	Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids [J]. Hepatology, 2018, 67: 534-548.
49	Ni Y, Lu M, Xu Y, et al. The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease [J]. Front Microbiol, 2022, 13: 908011.
50	Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota [J]. Gut Microbes, 2020, 11(2): 158-171.
51	Jadhav K, Xu Y, Xu Y, et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR [J]. Mol Metab, 2018, 9: 131-140.
52	Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis [J]. J Hepatol, 2020, 72(1): 25-33.
53	Arias N, Arboleya S, Allison J, et al. The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases [J]. Nutrients, 2020, 12: 2340.
54	Ji Y, Yin Y, Sun L, et al. The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement [J]. Int J Mol Sci, 2020, 21(9): 3066.
55	Tan X, Liu Y, Long J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease [J]. Mol Nutr Food Res, 2019, 63(17): e1900257.
56	Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target [J]. Front Pharmacol, 2019, 10: 1360.
57	Hernandez GV, Smith VA, Melnyk M, et al. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH [J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318: G582-G609.
58	Carpino G, Del Ben M, Pastori D, et al. Increased liver Localization of lipopolysaccharides in human and experimental NAFLD [J]. Hepatology, 2020, 72: 470-485.
59	Takeuchi O, Akira S. Pattern recognition receptors and inflammation [J]. Cell, 2010, 140(6): 805-820.
60	Chassaing B, Ley RE, Gewirtz AT. Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice [J]. Gastroenterology, 2014, 147(6): 1363-77. e17.
61	Zhu L, Baker RD, Zhu R, et al. Gut microbiota produce alcohol and contribute to NAFLD [J]. Gut, 2016, 65(7): 1232.
62	Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae [J]. Cell Metab, 2019, 30(4): 675-688.e7.
63	Wu L, Mo W, Feng J, et al. Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1α pathway [J]. Br J Pharmacol, 2020, 177(16): 3760-3777.
64	Trovato FM, Catalano D, Martines GF, et al. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions [J]. Clin Nutr, 2015, 34(1): 86-88.
65	Da Silva HE, Arendt BM, Noureldin SA, et al. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls [J]. J Acad Nutr Diet, 2014, 114(8): 1181-1194.
66	Nielsen LS, Danielsen KV, Sørensen TI. Short sleep duration as a possible cause of obesity: critical analysis of the epidemiological evidence [J]. Obes Rev, 2011, 12(2): 78-92.
67	Brondel L, Romer MA, Nougues PM, et al. Acute partial sleep deprivation increases food intake in healthy men [J]. Am J Clin Nutr, 2010, 91(6): 1550-1559.
68	St George A, Bauman A, Johnston A, et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease [J]. Hepatology, 2009, 50(1): 68-76.
69	Munukka E, Ahtiainen JP, Puigbó P, et al. Six-week endurance exercise alters gut metagenome that is not reflected in systemic metabolism in over-weight women [J]. Front Microbiol, 2018, 9: 2323.
70	Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: A review [J]. Jama, 2020, 323(12): 1175-1183.
71	Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease [J]. J Clin Invest, 2015, 125(1): 386-402.
72	Abdel-Razik A, Mousa N, Shabana W, et al. Rifaximin in nonal-coholic fatty liver disease: hit multiple targets with a single shot [J]. Eur J Gastroenterol Hepatol, 2018, 30(10): 1237-1246.
73	Jian J, Nie MT, Xiang B, et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids [J]. Front Pharmacol, 2022, 13: 841132.
74	Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, et al. Non-alcoholic fatty Liver diseases: from role of gut microbiota to microbial-based therapies [J]. Eur J Clin Microbiol Infect Dis, 2020, 39(4): 613-627.
75	Mohammed SK, Magdy YM, El-Waseef DA, et al. Modulation of hippocampal TLR4/BDNF signal pathway using probiotics is a step closer towards treating cognitive impairment in NASH Model [J]. Physiol Behav, 2020, 214: 112762.
76	Tang Y, Huang J, Zhang WY, et al. Effects of probiotics on nonalco-holic fatty liver disease: a systematic review and meta-analysis [J]. Therap Adv Gastroenterol, 2019, 12: 1756284819878046
77	Bomhof MR, Parnell JA, Ramay HR, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial [J]. Eur J Nutr (2019) 58: 1735-1745.
78	van der Beek CM, Canfora EE, Kip AM, et al. The prebiotic inulin improves substrate metabolism and promotes short-chain fatty acid production in overweight to obese men [J]. Metabolism, 2018, 87, 25-35.
79	Kanchanasurakit S, Kositamongkol C, Lanoi K, et al. Effects of synbiotics, probiotics, and prebiotics on liver enzymes of patients with non-alcoholic fatty liver disease: A systematic review and network meta-analysis [J]. Front Nutr, 2022, 9: 880014.
80	Liu L, Li P, Liu Y, Zhang Y. Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis [J]. Dig Dis Sci, 2019, 64(12): 3402-3412.
81	Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry [J]. Gastroenterology, 2021, 160: 183-192. e3.
82	de Groot P, Nikolic T, Pellegrini S, et al. Faecal Microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial [J]. Gut, 2021, 70: 92-105.
83	Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial [J]. Gastroenterology, 2021, 160: 145-157. e8.
84	Witjes JJ, Smits LP, Pekmez CT, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis [J]. Hepatol Commun, 2020, 4: 1578-1590.
85	Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial [J]. Am J Gastroenterol, 2020, 115: 1055-1065.

[1]	Rui Liu, Sijia Guo, Weibin Jing, Mingming Ma, Weihong Cao. Effect and mechanism of human adipose-derived stem cells on pulmonary inflammatory response in rats with 30% total body surface area third-degree scald [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2022, 15(06): 441-447.
[2]	Li Qiao, Chao Zhao, Hao Sun, Jie Chen, Jun Wang, Jinsong Zhang. Protective effects of Shenfu injection on alveolar cell injury induced by lipopolysaccharide [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2021, 14(05): 362-367.
[3]	Yanqun Xu, Ping Li, Xing Yang, Hui Xue. Lipopolysaccharide mediates interleukin-6 release from periodontal ligament cells by promoting hyaluronan receptor CD44 transfer to nuclear [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 335-344.
[4]	Xiuyang Zhang, Longfei Zhang, Shiyuan Chen, Yong Gao. Hypoxia-inducible factor-1α mediating the expression of monocarboxylate transporter-1 and participating in the protective effect of short-chain fatty acids on intestinal hypoxia [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 18-23.
[5]	nian Li, Jianjun Zhao, Jianyong Zhang, Ruizhen Zhao. Effect of human amniotic mesenchymal stem cell regulating MAPK signaling pathway of aquaporin 1 in acute lung injury [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 156-163.
[6]	Cong Peng, Xiaoying Luo, Yangqiu Bai, Xiaoke Jiang, Bingyong Zhang. Research progress in the interaction between intestinal flora metabolites and mesenchymal stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2022, 12(06): 367-371.
[7]	Na Li, Guozhen Zhu. Progress of research on the roles of gut microbiota and its metabolites in acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 215-219.
[8]	Lijun Zhu, Xi Qiao. Impact of gut microbiota on acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(03): 148-151.
[9]	Ziwei Zhang, Hong Lu. Advance on the effects of lipopolysaccharide receptor complex on iris pigment epithelial cells in acute anterior uveitis [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(03): 167-171.
[10]	Xiao Zhou, Dongchen Guo, Jin Lin, Meili Duan. Predictive value of serum cholinesterase in patients with septic acute kidney injury [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(02): 133-139.
[11]	Chengcheng Su, Yongqiang Ma, Shengkun Lang, Bin Liu, Luqing Wei, Wenjie Ji. Role and mechanism of action of mineralocorticoid receptorin lipopolysaccharide induced NLRP3 inflammasomes activation [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(05): 447-451.
[12]	Chunyan Bao, Xiujun Guan, Hong Qiu. Serum CHE, NT-proBNP, and PCT levels in patients with heart failure complicated with pulmonary infections: correlation with cardiac function and prognostic value [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(02): 146-151.
[13]	Haiyan Lin, Ning Cheng, Xin Huang, Wei Liu, Yuanyuan Wang. Effect of self-made Shugan Jianpi prescription on short chain fatty acids in patients with non-alcoholic fatty liver of stagnation of liver qi and spleen deficiency type [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(11): 871-876.
[14]	Zhengda Li, Yanbin Zhang, Maoxia Liu, Xinjing Yang. Protective effect of esmolol on sepsis-induced intestinal injury and its mechanism [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2023, 09(02): 90-95.
[15]	XiaoZhuo Tan, Chong Cao, YiKai Shao, QiYuan Yao. The effects of short chain fatty acids on host metabolism [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2022, 08(01): 46-51.

Please choose a citation manager

Content to export